Cytospire Therapeutics
PrivateLast Round
Series A
May 5, 2026
Total Funding Raised
$83M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Cytospire Therapeutics is a biotechnology company developing a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cytospire Therapeutics Comparables
Compare Cytospire Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Janux Therapeutics | 77% | |
| Ipsen | 76% | |
| Lava Therapeutics | 75% |
Cytospire Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 5, 2026 |
Cytospire Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Servier Ventures | Series A |
| Medical Incubator Japan | Series A |
| British Business Bank | Series A |
| 4BIO Capital | Seed, Series A |
| Abingworth | Series A, Seed |
| Pathway Bioventures | Series A |
| LifeArc Ventures | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Grew 47% QoQ, from 19 to 28 employees.
- May 27, 2026
Grew 17% QoQ, from 18 to 21 employees.
Recent news
Latest coverage and updates
- hiresSep 9, 2026
Cytospire Therapeutics Limited hired Sumeet as Chief Medical Officer on Sep 9th '26.
- hiresSep 8, 2026
Cytospire Therapeutics Limited hired Sumeet Ambarkhane as Chief Medical Officer on Sep 8th '26.
- is_developingSep 8, 2026
Cytospire Therapeutics Limited is developing portfolio of differentiated multispecific engager antibodies.
Cytospire Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cytospire Therapeutics's valuation, stock price, and market status.
Is Cytospire Therapeutics a public or private company?
Cytospire Therapeutics is a private company.
What is the current stock price of Cytospire Therapeutics?
Cytospire Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Cytospire Therapeutics worth (valuation)?
Valuation information for Cytospire Therapeutics is not publicly available.
Can I buy Cytospire Therapeutics stock?
Cytospire Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Cytospire Therapeutics's last funding round?
Cytospire Therapeutics's most recent funding round was Series A on May 5, 2026.
Who are the main investors in Cytospire Therapeutics?
Key investors in Cytospire Therapeutics include 4Bio Capital, Abingworth.
Will Cytospire Therapeutics IPO soon?
No public IPO plans have been announced for Cytospire Therapeutics.
How can I track Cytospire Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cytospire Therapeutics's secondary market activity and sign up for updates.